ArticleFrontiers in cellular neuroscience2022
Microglia-Specific Promoter Activities of
Open access · goldAbstract read
In one paragraph
Article in Frontiers in cellular neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- Spatial transcriptomics revealed the regulatory role of CCN1 to microglia distribution through region-specific cellular interactions.Genes & diseases · 2026Article
- Microglia heterogeneity in vascular dementia pathology.iScience · 2026Review
- Sphingomyelin synthase 1 as a potential upstream amplifier of microglial CSF1R signaling in neuropathic pain.Frontiers in molecular neuroscience · 2026Article
- Ubiquitous and Brain Cell-Type-Specific Promoters and Enhancers in Lentiviral Vectors.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Microglial replacement in a Sandhoff disease mouse model reveals myeloid-derived β-hexosaminidase is necessary for neuronal health.Nature communications · 2025Article
- Targeting CX3CR1 Signaling Dynamics: A Critical Determinant in the Temporal Regulation of Post-Stroke Neurorepair.Brain sciences · 2025Review
- Article
- Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.Signal transduction and targeted therapy · 2025Review
- Infiltrating peripheral monocyte TREM-1 mediates dopaminergic neuron injury in substantia nigra of Parkinson's disease model mice.Cell death & disease · 2025Article
- Exosome-related genes influence the progression of stroke through neuroinflammatory responses.Frontiers in neurology · 2025Article
- Alpha-Synuclein and Microglia in Parkinson's Disease: From Pathogenesis to Therapeutic Prospects.Journal of clinical medicine · 2024Review
- Myeloid-derived β-hexosaminidase is essential for neuronal health and lysosome function: implications for Sandhoff disease.bioRxiv : the preprint server for biology · 2024Article
- Integrating single-cell and spatially resolved transcriptomic strategies to survey the astrocyte response to stroke in male mice.Nature communications · 2024Article
- Established and emerging techniques for the study of microglia: visualization, depletion, and fate mapping.Frontiers in cellular neuroscience · 2024Review
- Microglia targeting by adeno-associated viral vectors.Frontiers in immunology · 2024Review
- Eradication of human immunodeficiency virus-1 reservoir in the brain microglia.Neural regeneration research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Sahil ShahCenter for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Lilly M WongUniversity of North Carolina HIV Cure Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Kendra EllisCenter for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Brittany BodnarCenter for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Sami SaribasCenter for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Julia TingCenter for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Zhengyu WeiCenter for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Yuyang TangUniversity of North Carolina HIV Cure Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Xianwei WangCenter for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Hong WangCenter for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Binhua LingSouthwest National Primate Research Center, Host-Pathogen Interaction Program, Texas Biomedical Research Institute, San Antonio, TX, United States.
David M MargolisUniversity of North Carolina HIV Cure Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
J Victor GarciaInternational Center for the Advancement of Translational Science, Division of Infectious Diseases, UNC Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Wenhui HuCenter for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Guochun JiangUniversity of North Carolina HIV Cure Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Temple University · USUniversity of North Carolina at Chapel Hill · USTexas Biomedical Research Institute · US
Funding
Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4MThe Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7MCollaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2021 to 2026
$31.6MBrain myeloid cell-targeted multiplexed gene editing for SIV/HIV eradicationR01MH130193 · NIMH · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Wenhui Hu, Binhua Julie Ling · 2022 to 2026
$4.0MCD4 T cell-targeted nanoparticle in vivo delivery of CRISPR/Cas9 genome editors for HIV cureR01AI145034 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI HU, WENHUI · 2019 to 2023
$3.8MLentivirus-like particle specific delivery of Cas12 ribonucleoprotein (RNP) to HIV reservoir cells in vivo for an HIV cureR01AI174301 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI Wenhui Hu, Qingsheng Li · 2023 to 2026
$3.5MCNS Myeloid Cells as SIV Reservoirs: Persistent Infection and ReboundR01MH116844 · NIMH · TULANE UNIVERSITY OF LOUISIANA · PI LING, BINHUA "JULIE" · 2018 to 2022
$3.4MHIV, Methamphetamine and Human iPSC-derived Microglia-containing Cerebral OrganoidsR01DA051893 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI HO, WENZHE, HU, WENHUI · 2020 to 2024
$3.1MLong-term microglia-targeted endogenous retrovirus-like particle (ERVLP) delivery of Cas12f editor to cure HIVR01DA056876 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Wenhui Hu · 2022 to 2026
$3.0MCharacterize replication competent myeloid reservoirs in the central nervous systemR21MH128034 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JIANG, GUOCHUN · 2021 to 2022
$443kNIAID NIH HHS R01 AI145034NIAID NIH HHS UM1 AI164567NIDA NIH HHS R01 DA051893NIDA NIH HHS R01 DA056876NIH HHS P51 OD011104NIH HHS P51 OD011133NIMH NIH HHS R01 MH116844NIMH NIH HHS R01 MH130193NIMH NIH HHS R21 MH128034
Abstract
Adeno-associated virus (AAV)-mediated genetic targeting of microglia remains a challenge. Overcoming this hurdle is essential for gene editing in the central nervous system (CNS). Here, we characterized the minimal/native promoter of the
Indexed as
astrocytesCD68gene editinggene therapyHexBmicroglia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.